In Los Angeles, New York, Houston, Philadelphia, and Washington, D.C., a National Institutes of Health funded clinical trial, known as INTEGRA, is evaluating the efficacy of delivering integrated HIV and substance use disorder care via mobile clinics.
Breadcrumb
- Home
- Resources and Tools
Resources and Tools
A recent study published in Drug and Alcohol Dependence found evidence for racial/ethnic disparities in buprenorphine distribution across the United States.
Transgender people and communities, including nonbinary people, have specific needs within harm reduction programs.
This report analyzes the issues and trends underlying the syndemics of HIV, SUD, and viral hepatitis in West Virginia.
The HIV and OUD Service and Funding Matrices Template supports state health departments in identifying opportunities for enhanced coordination between HIV and OUD funding and service provision.
In recent years, the gap in the rate of opioid overdoses among Black and white Americans has narrowed significantly, with increases in Black mortality driven in part by the addition of synthetic opioids to other drugs.
This technical package, a collaborative effort between CDC and NASTAD, provides a broad framework as well as evidence-informed strategies and approaches to support the planning, design, implementation, and sustainability of new and existing syringe services programs (SSPs).
Opioid agonist treatment (OAT) is the provision of medications (methadone and buprenorphine) that activate the opioid receptors to prevent withdrawal and reduce cravings for opioids.
This publication, part of SAMHSA's Evidence Based Resource Guide series, addresses the co-occurrence of HIV and mental illness and/or SUD.
Pagination
- Previous page ‹‹
- Page 2
- Next page ››